Zoetis (NYSE:ZTS) Raised to “Hold” at Zacks Research

Zoetis (NYSE:ZTS) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

A number of other research analysts have also issued reports on ZTS. BNP Paribas Exane reduced their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Stifel Nicolaus dropped their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. Morgan Stanley set a $85.00 target price on Zoetis in a research note on Friday, August 7th. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, HSBC reduced their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $98.40.

Zoetis Trading Down 3.4%

Shares of ZTS stock opened at $78.25 on Monday. The business’s 50 day moving average is $74.84 and its two-hundred day moving average is $94.35. Zoetis has a 12-month low of $68.77 and a 12-month high of $147.46.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the business earned $1.76 earnings per share. Zoetis’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts predict that Zoetis will post 6.15 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its stake in Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after acquiring an additional 91 shares in the last quarter. Lipe & Dalton grew its holdings in shares of Zoetis by 2.2% in the first quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares in the last quarter. Root Financial Partners LLC lifted its holdings in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the period. Rexford Capital Inc. lifted its holdings in Zoetis by 5.3% during the first quarter. Rexford Capital Inc. now owns 2,352 shares of the company’s stock worth $278,000 after acquiring an additional 118 shares during the period. Finally, Valmark Advisers Inc. lifted its holdings in Zoetis by 7.7% during the first quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock worth $207,000 after acquiring an additional 125 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.